References
- Mccormick, M. H., Mcguire, J. M., Pittrenger, G. E., Pittrenger, R. C. and Stark, W. M. : Vancomycin, a new antibiotic. I. Chemical and biologic properties. Antibiot. Annu.3, 606 (1955-1956).
- Pfeiffer, R. R. : Structural features of vancomycin. Rev. Infect. Dis. 3, 205 (1981) https://doi.org/10.1093/clinids/3.Supplement_2.S205
- Fekety, R. : Vancomycin. Med. Clin. North Am. 66, 175 (1982) https://doi.org/10.1016/S0025-7125(16)31451-1
- Cook, F. V. and Farrar, W. E. : Vancomycin revisited. Ann. Intern. Med. 88, 813 (1978) https://doi.org/10.7326/0003-4819-88-6-813
- Kucers, A., Crowe, S. M., Grayson, M. L. and Hoy, J. F. : The Use of Antibiotics. A clinical Review of Antibacterial, Antifungal and Antiviral Drugs. Fifth ed., Oxford, Oxford Univ Press, p761 (1977)
- CDC. Staphylococcus areus resistant to vancomycin---United States, 2002. MMWR 51, 565 (2002)
- Gerald, K. McEvoy : AHFS drug information 2006. Bethesda, MD, American Society of Hospital Pharmacists, Inc. p473 (2006)
- CDC : Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR 44, 1 (1995)
- Davis, R. L., Smith, A. L. and Koup, J. R. : The "red man's syndrome" and slow infusion of vancomycin. Ann. Intern. Med. 104, 285 (1986)
- Elting, L. S., Rubenstein, E. B., Kurtin, D., Rolston, K. V., Fangtang, J., Martin, C. G., Raad, I. I., Whimbey, E. E., Manzullo, E. and Bodey, G. P. : Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer 83, 2597 (1998) https://doi.org/10.1002/(SICI)1097-0142(19981215)83:12<2597::AID-CNCR27>3.0.CO;2-L
- Hughes, W. T., Armstrong, D., Bodey, G. P., Brown, A. E., Edwards, J. E., Feld, R., Pizzo, P., Rolston, K. V., Shenep, J. L. and Young, L. S. : 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin. Infect. Dis. 25, 551 (1977) https://doi.org/10.1086/513764
- Kunin, C. M. : Guidelines for peer review. Veterans Administration Ad Hoc Interdisciplinary Advisory Committee on Antimicrobial Usage. Audits of antimicrobial usage. JAMA 237, 1001 (1977)
- Moellering, R. C. : Pharmacokinetics of vancomycin. J. Antimicrob. Chemother. 14, 43 (1984)
- Cunha, B. A. and Ristuccia, A. M. : Clinical usefulness of vancomycin. Clin. Pharm. 2, 417 (1983)
- Johnson, C. C. and Tunkel, A. R. : Viridans streptococci, Groups C and G streptococci, and Gemella morbillorum. In: Mandell, G. L., Bennett, J. E. and Dolin, R., eds. Principles and practice of infectious diseases. 6th ed. Vol 2. Philadelphia: Churchill Livingstone, p2434 (2005)
- Khurana, C. and de Belder, M. A. : Red-man syndrome after vancomycin: potential cross-reactivity with teicoplanin. Postgrad. Med. J. 75, 41 (1999) https://doi.org/10.1136/pgmj.75.879.41
- Ambrose, P. J. and Winter, M. E. : Vancomycin, In: Michael E. Winter. Basic Clinical Pharmacolinetics. 4th Ed. Philadelphia: Lippincott Williams & Wilkins, p451 (2004)
- Reginald, F., Captitano, B., Gary, E. and Matzke, R. : Vancomycin. In: John E. Murphy. Clinical pharmacokinetics. 3rd ed. Bethesda, Maryland: the American Society of Health- System Pharmacists Inc., p349 (2005)
- Iwamoto, T., Kagawa, Y. and Kojima, M. : Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol. Pharm. Bull. 26, 876 (2003)